AI assistant
Vaxcyte, Inc. — Director's Dealing 2024
Mar 5, 2024
31100_dirs_2024-03-04_5f02c9a5-e0a4-4198-88e0-0183db1748f0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-02-29
Reporting Person: PICKERING GRANT (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-29 | Common Stock | A | 45000 | — | Acquired | 420814 | Direct |
| 2024-03-01 | Common Stock | S | 506 | $73.038 | Disposed | 149472 | Indirect |
| 2024-03-01 | Common Stock | S | 439 | $73.536 | Disposed | 149033 | Indirect |
| 2024-03-01 | Common Stock | S | 363 | $74.693 | Disposed | 148670 | Indirect |
| 2024-03-01 | Common Stock | S | 366 | $72.97 | Disposed | 149612 | Indirect |
| 2024-03-01 | Common Stock | S | 591 | $73.59 | Disposed | 149021 | Indirect |
| 2024-03-01 | Common Stock | S | 351 | $74.779 | Disposed | 148670 | Indirect |
| 2024-03-02 | Common Stock | F | 7967 | $71.55 | Disposed | 412847 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-29 | Stock Option (right to buy) | $73.82 | A | 205000 | Acquired | 2034-02-28 | Common Stock (205000) | Direct |
Footnotes
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.
F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $73.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.55 to $74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.40 to $73.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F8: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F9: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $73.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F10: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F11: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.